Albireo Pharma Inc RSI
Quel est le RSI de Albireo Pharma Inc?
Le RSI de Albireo Pharma Inc est 68.03
Quelle est la définition de RSI?
L'indice de force relative (RSI 14) est un indicateur de dynamique qui compare l'ampleur des gains et des pertes sur une période donnée afin de mesurer la vitesse et l'évolution des mouvements de prix d'un titre.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI des entreprises dans Health Care secteur sur NASDAQ par rapport à Albireo Pharma Inc
Que fait Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Entreprises avec rsi similaire à Albireo Pharma Inc
- US Masters Residential Property Fund a RSI de 68.01
- United Airlines a RSI de 68.01
- TXCOM Societe Anonyme a RSI de 68.02
- Tiaan Ayurvedic & Herbs a RSI de 68.02
- Hertz Global a RSI de 68.02
- PI Industries a RSI de 68.02
- Albireo Pharma Inc a RSI de 68.03
- Manulife a RSI de 68.04
- Zeta Global a RSI de 68.04
- Digicontent a RSI de 68.04
- Gowest Gold a RSI de 68.05
- CCUR a RSI de 68.05
- Concurrent Computer a RSI de 68.05